Venous thromboembolism (VTE) is a silent disease that is sometimes overlooked by patients and clinicians. Due to a general lack of awareness about VTE, a condition that may include deep vein thrombosis (DVT) and/or pulmonary embolism (PE), patients are not often diagnosed accurately and given timely treatment, resulting in high disease morbidity. Improving the awareness […]
This article is part 2 in a series on haemophilia diagnostics and therapeutics. The first article, which can be viewed here, provides an overview of its clinical presentation, diagnosis and treatment. As researchers develop innovative new treatments for haemophilia, clinical lab professionals should be aware of these developments and their potential impact on diagnostic workflows.
Emerging haemophilia therapies highlight a need for quality diagnostics Read More »
With new haemophilia therapeutics on the horizon, greater attention must be paid to accurate and timely diagnosis of the disease. To help clinical lab professionals better understand haemophilia and support emerging innovations that can improve patient outcomes, this article provides a brief introduction to its clinical presentation, diagnosis and treatment. What is haemophilia and how
Haemophilia diagnostics and therapeutics: a brief introduction Read More »
At the Roche Diagnostics-sponsored satellite symposium ‘From Basic Research to Clinical Data: the Future of Patient Management’ hosted during the International Society for Haemostasis (ISTH) 2021 congress, Prof. Jonathan Douxfils discussed the value of monitoring direct oral anticoagulants (DOAC) and contact pathway inhibitors. While DOACs were developed without the need for routine laboratory monitoring, the
Measurement of direct oral anticoagulants (DOACs) and contact pathway inhibitors Read More »
At the Roche Diagnostics-sponsored satellite symposium ‘From Basic Research to Clinical Data: the Future of Patient Management’ hosted during the International Society for Haemostasis (ISTH) 2021 congress, Dr Jean M Connors MD gave an insightful presentation on thrombo-inflammation in the COVID-19 era. The disease COVID-19 has been identified as a hypercoagulable state. The development of
COVID-19 and antithrombotics: What we know now Read More »
Since the onset of the COVID-19 pandemic, mounting evidence has shown that patients with severe infection are more likely to have COVID-associated coagulopathies. The global coagulation community responded rapidly with various societies reviewing available data and providing recommendations and educational resources [1]. Researchers also spearheaded a multi-platform randomised trial to support the community to make
Four ways the global coagulation community responded to the COVID-19 pandemic Read More »
Vaccine-induced thrombotic thrombocytopenia (VITT), a condition characterised by blood clots resulting from COVID-19 vaccinations, is a rare but serious concern in the fight against COVID-19. This Q&A with Dr Ng Heng Joo, Head & Senior Consultant in the Department of Haematology at Singapore General Hospital, explores the pathophysiology, diagnosis of VITT and clinical management of
COVID-19 vaccines, blood clots and anticoagulation therapy: insights from Dr Ng Heng Joo Read More »
Infection with COVID-19 has been associated with thrombosis, or blood clots, involving the veins and arteries. The risk of blood clots is highest for individuals admitted to hospital with COVID-19 infection, occurring in about 5% of people admitted to a regular hospital ward and up to 20% for those in the intensive care unit (ICU),
How coagulation diagnostics support COVID-19 vaccination and patient management Read More »
The ongoing COVID-19 pandemic has had a profound worldwide impact on the Thrombosis and Hemostasis community. Nevertheless, the pace of COVID-19 coagulation-related research has continued to accelerate and has established the role of laboratory coagulation data for many purposes, including disease prognosis and outcome. Although the pathogenesis of the COVID-19-induced coagulopathy has not yet been
Coagulation during COVID-19 and beyond: diagnostic challenges and opportunities Read More »
The widely used dietary supplement, vitamin B7 or biotin, raised concerns last year. It was found to interfere with some lab tests, prompting the US Food & Drug Administration (FDA) to issue a warning. Such interference is not new to laboratory medicine and will continue to be an issue as new drugs, tests and supplements come to market. And
3 steps to mitigate the impact of interference Read More »
Subscribe to Lab Insights latest news and update
Join over 3,000 HCPs receiving insights in their inbox.
